CoChat
Sign Up
Cited by 26Hypothalamic control of reproductive hormonesHormonal and reproductive studiesGrowth Hormone and Insulin-like Growth Factors

Therapeutic uses of aromatase inhibitors in men

de Ronde, Willem·2007·Current Opinion in Endocrinology, Diabetes & Obesity
DOI 10.1097/med.0b013e328121aad2
Open this paper in CoChat — free account

Abstract

PURPOSE OF REVIEW: In men estrogens are important for achieving and maintaining bone mass, epiphysial maturation and feedback on gonadotrophin secretion. Potent aromatase inhibitors offer a convenient way to suppress estrogen production in men. This review aims to present an overview of the potential indications for aromatase inhibitors in men and to discuss results of clinical trials. RECENT FINDINGS: Aromatase inhibitors are particularly useful to delay epiphysial maturation and increase predicted adult height in boys with pubertas praecox, idiopathic short stature and constitutional delay of puberty. In older men with late-onset hypogonadism aromatase inhibitors improve plasma testosterone levels but evidence for long-term benefit is presently lacking. Preliminary evidence shows no detrimental effects of aromatase inhibition on bone metabolism in men. SUMMARY: Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men and may be used to increase adult height in boys with pubertas praecox, idiopathic short stature and constitutional delay of puberty. Long-term efficacy and safety is not established in adult men and their use in older men with late-onset hypogonadism is therefore not yet recommended.

Integrity signals

Registry

Crossref · 10.1097/med.0b013e328121aad2

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aromatase inhibitors use in women is associated with a modest increase in bone resorption.

    “Aromatase inhibitors were proven to be safe, convenient and effective for the treatment of hormone sensitive breast cancer in women although their use is associated with a modest increase in bone resorption [2,3].”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [3]

  • Aromatase inhibitors were proven to be safe, convenient and effective for the treatment of hormone sensitive breast cancer in women.

    “Aromatase inhibitors were proven to be safe, convenient and effective for the treatment of hormone sensitive breast cancer in women although their use is associated with a modest increase in bone resorption [2,3].”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [3]

  • Long-term use of potent aromatase inhibitors in postmenopausal women is associated with adverse effects on bone.

    “In postmenopausal women with breast carcinoma, long-term use of potent aromatase inhibitors reduces circulating estradiol levels by 88% [31] and is associated with adverse effects on bone [2,3].”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [3]

  • Long-term use in postmenopausal women is associated with a moderate increase in bone resorption and a modest decrease in BMD compared with placebo.

    “Long-term use in postmenopausal women is associated with a moderate increase in bone resorption and a modest decrease in BMD compared with placebo [2,3].”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [3]

  • Extensive experience with third-generation aromatase inhibitors in postmenopausal women did not reveal major side effects related to their use.

    “Extensive experience with third-generation aromatase inhibitors in postmenopausal women did not reveal major side effects related to their use.”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [3]

Cites

1 retracted

Flagged first, then by citations

8 of the 69 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
de Ronde, W.
Venue
Current Opinion in Endocrinology, Diabetes & Obesity
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-06
Volume
14
Issue
3
Pages
235-240
ISSN
1752-296X (ISSN-L)
DOI
10.1097/med.0b013e328121aad2
OpenAlex
W2790224787
Cited by
26
References
69
Citations by year
2019: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 1
FWCI
0.52
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
aromatase inhibitors, men, estrogen suppression, idiopathic short stature, constitutional delay of growth and puberty, adult height, andropause, testosterone, bone metabolism
MeSH terms
Estrogen Antagonists, Estrogens, Humans, Luteinizing Hormone, Male, Phenotype, Testosterone, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review